These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 19857448

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT, Stefaniak ME, Patterson NB, Chen P, Konovalova S, Limbach K, Campo JJ, Ettyreddy D, Li S, Dubovsky F, Richie TL, King CR, Long CA, Doolan DL.
    Vaccine; 2010 Apr 19; 28(18):3201-10. PubMed ID: 20188680
    [Abstract] [Full Text] [Related]

  • 3. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garçon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J.
    Vaccine; 2005 Mar 18; 23(17-18):2243-50. PubMed ID: 15755604
    [Abstract] [Full Text] [Related]

  • 4. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA, Kester KE, Cummings JF, Burge JR, Voss G, Delchambre M, Garçon N, Tang DB, Cohen JD, Heppner DG.
    Vaccine; 2006 Oct 30; 24(42-43):6483-92. PubMed ID: 16904798
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys.
    Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, Kester KE, Holland CA, Voss G, Cohen J, Stewart AV, Miller RS, Ballou WR, Heppner DG.
    Am J Trop Med Hyg; 2004 May 30; 70(5):499-509. PubMed ID: 15155981
    [Abstract] [Full Text] [Related]

  • 6. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG.
    Vaccine; 2007 May 22; 25(21):4203-12. PubMed ID: 17442466
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.
    Cortés A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, Anders RF.
    Infect Immun; 2005 Jan 22; 73(1):422-30. PubMed ID: 15618180
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV, Biswas S, Pillai CR, Saxena RK.
    Vaccine; 2008 Aug 18; 26(35):4526-35. PubMed ID: 18590786
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE, Gray Heppner D, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J, RTS,S/TRAP Group.
    Vaccine; 2014 Nov 20; 32(49):6683-91. PubMed ID: 24950358
    [Abstract] [Full Text] [Related]

  • 19. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G.
    Vaccine; 2007 Jan 05; 25(3):490-9. PubMed ID: 16949181
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
    Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ.
    Vaccine; 2005 Jul 14; 23(32):4148-57. PubMed ID: 15964483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.